Imagine an inspector asks a simple question:
"Show me how this complaint led to your CAPA decision."
For some med tech manufacturers, that answer is fast. For others, it starts a scavenger hunt.
Someone checks the complaint system. Someone else opens a spreadsheet. A third person searches email. The CAPA record exists, but the risk analysis is in another folder. The design history reference is in a PDF. The supplier investigation is buried in a shared drive.
None of this means the company is careless. It means the quality story is fragmented.
QMSR raises the importance of having a connected, inspection-ready quality system. FDA's updated Part 820 incorporates ISO 13485:2016 and modernizes device quality system requirements around a more internationally aligned QMS framework.
For manufacturers, the real challenge is not simply updating procedures. It is making sure evidence can move across the lifecycle: design, purchasing, production, monitoring, complaint handling, CAPA, and management review.
Quality teams should pressure-test their systems before they are under regulatory pressure.
Pick a product. Pick a complaint. Pick a supplier issue. Pick a design change. Then ask: Can we reconstruct the full story quickly, accurately, and with confidence?
What manufacturers should pay attention to:
Traceability is the heart of QMSR readiness. The best teams will focus less on "Where is the document?" and more on "Can we show the relationship between risk, action, and evidence?"
Bottom line: If your quality story is hard to tell internally, it will be even harder to defend externally.